Congress Materials

FILTER
Select topic(s):
Content type:
Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
Bruce Strober, Luis Puig, Andrew Blauvelt, et al.
A matching-adjusted indirect comparison of the efficacy of bimekizumab and guselkumab at 52 weeks for the treatment of psoriatic arthritis
Richard B. Warren, Iain B. McInnes, Peter Nash, et al.
A matching-adjusted indirect comparison of the efficacy of bimekizumab and guselkumab at 52 weeks for the treatment of psoriatic arthritis
Richard B. Warren, Iain B. McInnes, Peter Nash, et al.
Achievement of Low Disease Activity Over 52 Weeks in Patients with Active Axial Spondyloarthritis on Bimekizumab Treatment: Results from the Phase 3 Studies BE MOBILE 1 and BE MOBILE 2
Xenofon Baraliakos, Sofia Ramiro, Marina Magrey, et al.
An Exploratory Analysis of the Potential Disconnect Between Objective Inflammatory Response and Clinical Response Following Certolizumab Pegol Treatment in Patients with Active Axial Spondyloarthritis
Martin Rudwaleit, Filip Van den Bosch, Helena Marzo-Ortega, et al.
Association of DLQI 0/1 with absolute PASI by age and sex in patients with psoriasis treated with certolizumab pegol: Three-year results from three phase 3 trials
Sandra McBride, Jolanta Węgłowska, Peter Wolf, et al.
Association of EQ VAS with treatment benefits and patient-reported benefits in patients with moderate to severe psoriasis – data from the German national psoriasis registry PsoBest
Matthias Augustin, Toni M. Janke, Tanja Heidbrede, et al.
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Joseph F. Merola, Curdin Conrad, Philip Hampton, et al.
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Joseph F. Merola, Curdin Conrad, Philip Hampton, et al.
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Joseph F. Merola, Curdin Conrad, Philip Hampton, et al.
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Joseph F. Merola, Curdin Conrad, Philip Hampton, et al.
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Joseph F. Merola, Curdin Conrad, Philip Hampton, et al.
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Joseph F. Merola, Curdin Conrad, Philip Hampton, et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Diamant Thaci, April Armstrong, Kenneth B. Gordon, et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Diamant Thaci, April Armstrong, Kenneth B. Gordon, et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Diamant Thaci, April Armstrong, Kenneth B. Gordon, et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Diamant Thaci, April Armstrong, Kenneth B. Gordon, et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Diamant Thaci, April Armstrong, Kenneth B. Gordon, et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Diamant Thaci, April Armstrong, Kenneth B. Gordon, et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Diamant Thaci, April Armstrong, Kenneth B. Gordon, et al.
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
Mark Lebwohl, Bruce Strober, Richard G. Langley, et al.
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
Mark Lebwohl, Bruce Strober, Richard G. Langley, et al.
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
M. Lebwohl, Bruce Strober, Richard G. Langley, et al.
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
Mark Lebwohl, Bruce Strober, Richard G. Langley, et al.
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
Mark Lebwohl, Bruce Strober, Richard Langley, et al.
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
Mark Lebwohl, Bruce Strober, Richard G. Langley, et al.
Bimekizumab 4-year maintenance of responses in Week 16 responders with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension phase 3 trial
Andrew Blauvelt, Peter Foley, Richard G. Langley, et al.
Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
Marina Magrey, Marleen G.H. Van de Sande, Maxime Breban, et al.
Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
Marina Magrey, Marleen G.H. Van de Sande, Maxime Breban, et al.
Bimekizumab and secukinumab comparative effectiveness in hidradenitis suppurativa: Indirect treatment comparisons at Week 16 and 1 Year
Amit Garg, Leah Davis, Vanessa Taieb, et al.
Bimekizumab clinical efficacy translates into benefits in patient-perceived symptoms and quality of life in patients with moderate to severe plaque psoriasis: Two-year data from BE RADIANT
Andrew Blauvelt, Joseph F. Merola, Georgios Kokolakis, et al.
Bimekizumab continuous maintenance of response at every visit through two years in patients with moderate to severe plaque psoriasis: Post-hoc results from five phase 3/3b trials
Andrew Blauvelt, Curdin Conrad, Antonio Costanzo, et al.
Bimekizumab continuous maintenance of response at every visit through two years in patients with moderate to severe plaque psoriasis: Post-hoc results from five phase 3/3b trials
Andrew Blauvelt, Curdin Conrad, Antonio Costanzo, et al.
Bimekizumab continuous maintenance of response at every visit through two years in patients with moderate to severe plaque psoriasis: Post-hoc results from five phase 3/3b trials
Andrew Blauvelt, Curdin Conrad, Antonio Costanzo, et al.
Bimekizumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Pooled analysis from up to 3 years of treatment in 5 phase 3/3b clinical trials
Bruce Strober, James G. Krueger, Nina Magnolo, et al.
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
Iain B. McInnes, Philip J. Mease, Yoshiya Tanaka, et al.
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
Iain B. McInnes, Philip J. Mease, Yoshiya Tanaka, et al.
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
Iain B. McInnes, Philip J. Mease, Yoshiya Tanaka, et al.
Bimekizumab efficacy and safety in biologic DMARD-naïve patients with psoriatic arthritis was consistent with or without methotrexate: 52-Week results from the Phase 3 active reference study BE OPTIMAL
Iain B. McInnes, Philip J. Mease, Yoshiya Tanaka, et al.
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
Iain B. McInnes, Philip J. Mease, Yoshiya Tanaka, et al.
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
Iain B. McInnes, Philip J. Mease, Yoshiya Tanaka, et al.
Bimekizumab efficacy and safety in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: 3 year results from BE BRIGHT, a multicenter, open label, phase 3 study
Yukari Okubo, Yayoi Tada, Hidetoshi Takahashi, et al.
Bimekizumab Efficacy and Safety in Patients with Active Psoriatic Arthritis and Psoriasis: 52-Week Results from the BE OPTIMAL and BE COMPLETE Phase 3 Randomised, Placebo-Controlled Studies
Diamant Thaci, Akihiko Asahina, Mark Lebwohl, et al.
Bimekizumab efficacy and safety through 4 years in moderate to severe plaque psoriasis: Long-term results from the BE SURE trial and BE BRIGHT open-label extension
Diamant Thaci, Luis Puig, Joseph F. Merola, et al.
Bimekizumab Efficacy by Disease Duration in Patients with Moderate to Severe Hidradenitis Suppurativa: Week 48 Results from BE HEARD I & II
Alexa B. Kimball, Vivian Y Shi, Martina Porter, et al.
Bimekizumab efficacy in moderate to severe plaque psoriasis: Improvements in symptom severity assessed using Psoriasis Symptoms and Impacts Measure (P-SIM) thresholds in BE VIVID and BE SURE
Alice B. Gottlieb, Richard B. Warren, Matthias Augustin, et al.
Bimekizumab efficacy in patients with moderate to severe plaque psoriasis and hypertension, elevated body mass index or hyperglycaemia: Results through one year of treatment in four phase 3/3b trials
April Armstrong, Steven Feldman, Paolo Gisondi, et al.
Bimekizumab efficacy in patients with moderate to severe plaque psoriasis and hypertension, elevated body mass index, or hyperglycemia: Results through 3 years of treatment in 5 phase 3/3b trials
April Armstrong, Steven R. Feldman, Paolo Gisondi, et al.
Bimekizumab efficacy in patients with moderate to severe plaque psoriasis: Psoriasis Symptoms and Impacts Measure (P-SIM) results across 14 items through Week 16 of three pivotal phase 3 trials
Alice B. Gottlieb, Akihiko Asahina, Tsen F. Tsai, et al.
Bimekizumab efficacy through 144 weeks in moderate to severe plaque psoriasis: Patient-reported outcomes from BE RADIANT
Alice B. Gottlieb, Paolo Gisondi, Paul G. Sator, et al.
Bimekizumab efficacy through 3 years in patients with moderate to severe plaque psoriasis: Long-term pooled analysis from BE BRIGHT
Mark Lebwohl, Bruce Strober, Peter Foley, et al.
Bimekizumab efficacy through Year 1 in patients with moderate to severe plaque psoriasis who had not achieved a PASI 90 response by Week 16: A pooled analysis from four phase 3/3b trials
George Han, Alice B. Gottlieb, April Armstrong, et al.
Bimekizumab impact on cardiovascular inflammation markers in moderate to severe plaque psoriasis: Results from phase 3 trials
Richard B. Warren, Richard G. Langley, Georgios Kokolakis, et al.
Bimekizumab impact on concomitant rescue interventions in patients with moderate to severe hidradenitis suppurativa in BE HEARD I & II
Falk G. Bechara, Christopher J. Sayed, Stephanie Goldberg, et al.
Bimekizumab Impact on Core Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Domains for Patients with Psoriatic Arthritis: 52-Week Results from Four Phase 3 Studies
Joseph F. Merola, Philip J. Mease, Atul Deodhar, et al.
Bimekizumab Impact on Dichotomous IHS4 Response Levels in Patients with Moderate to Severe Hidradenitis Suppurativa: Results up to Week 48 from BE HEARD I & II
Thrasyvoulos Tzellos, Afsaneh Alavi, Athanassios Kyrgidis, et al.
Bimekizumab impact on draining tunnels in patients with moderate to severe hidradenitis suppurativa: Pooled 48-week data from BE HEARD I & II
Christos C Zouboulis, Jennifer Hsiao, Ziad Reguiai, et al.
Bimekizumab Impact on Health-Related Quality of Life and Physical Function in Patients with Active Psoriatic Arthritis who were Biologic DMARD-Naïve or had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3, Randomized
Dafna D. Gladman, Laure Gossec, M. Elaine Husni, et al.
Bimekizumab impact on joint and pain outcomes in patients with active psoriatic arthritis and psoriasis: Pooled 16-week results from the BE OPTIMAL and BE COMPLETE phase 3 randomised, placebo-controlled studies
Akimichi Morita, Joseph F. Merola, Laura C. Coates, et al.
Bimekizumab Impact on Lesion Count by Anatomical Region in Moderate to Severe Hidradenitis Suppurativa: Results to Week 48 from BE HEARD I & II
Hessel H. van der Zee, Brian Kirby, Falk G. Bechara, et al.
Bimekizumab improved outcomes in disease core domains in patients with active psoriatic arthritis and psoriasis: Pooled 16-week results from the BE OPTIMAL and BE COMPLETE phase 3 randomised, placebo-controlled studies
Yoshinori Umezawa, Joseph F. Merola, Laura C. Coates, et al.
Bimekizumab Improved Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies
Maureen Dubreuil, Karl Gaffney, Jonathan Kay, et al.
Bimekizumab improvement in three Dermatology Life Quality Index (DLQI) items capturing aspects most burdensome to patients with moderate to severe plaque psoriasis
Matthias Augustin, Jennifer Cather, Kim A. Papp, et al.
Bimekizumab improves key patient-reported symptoms of axial spondyloarthritis including spinal pain and fatigue: Results from two phase 3 studies
Philip J. Mease, Atul Deodhar, Maxime Dougados, et al.
Bimekizumab in patients with active non-radiographic and radiographic axial spondyloarthritis: 52-week efficacy and safety from the BE MOBILE phase 3 studies
Joseph F. Merola, Xenofon Baraliakos, Diamant Thaci, et al.
Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa: A Focus on Patient Quality of Life and Depth of Responses from BE HEARD I & II to Week 48
Joslyn S. Kirby, Steven Daveluy, Andreas Pinter, et al.
Bimekizumab in patients with moderate to severe plaque psoriasis: Analysis of mental health and associated disorders
Andrew Blauvelt, April Armstrong, Joseph F. Merola, et al.
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients with Psoriatic Arthritis who were Responders at Week 16: Results from a Phase 3, Active Reference Study
William Tillett, Joseph F. Merola, Yoshiya Tanaka, et al.
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients with Psoriatic Arthritis Who Were Responders at Week 16: Results from BE OPTIMAL, a Phase 3, Active Reference Study
William Tillett, Joseph F. Merola, Yoshiya Tanaka, et al.
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to TNF-α Inhibitors who were Responders at Week 16: Results from a Phase 3, Randomized Study
William Tillett, Joseph F. Merola, Yoshiya Tanaka, et al.
Bimekizumab Maintained Improvements in Efficacy Endpoints and Had a Consistent Safety Profile Through 52 Weeks in Patients with Axial Spondyloarthritis: Results from Two Parallel Phase 3 Studies
Xenofon Baraliakos, Atul Deodhar, Desiree van der Heijde, et al.
Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from the Phase 3 Studies BE MOBILE 1 and BE MOBILE 2
Fabian Proft, Desiree van der Heijde, Xenofon Baraliakos, et al.
Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from the Phase 3 Studies BE MOBILE 1 and BE MOBILE 2
Fabian Proft, Desiree van der Heijde, Xenofon Baraliakos, et al.
Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
Bruce Strober, Luis Puig, Andrew Blauvelt, et al.
Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
Bruce Strober, Luis Puig, Andrew Blauvelt, et al.
Bimekizumab Maintenance of Response and Safety in Patients with Moderate to Severe Plaque Psoriasis: Results from the Open-label Extension Period (Weeks 48–144) of the BE RADIANT Phase 3b Trial
Bruce Strober, Luis Puig, Andrew Blauvelt, et al.
Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open‑label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
Bruce Strober, Luis Puig, Andrew Blauvelt, et al.
Bimekizumab Reduced MRI Inflammatory Lesions in Patients with Axial Spondyloarthritis: Week 52 Results from the BE MOBILE 1 and 2 Phase 3 Studies
Xenofon Baraliakos, Victoria Navarro-Compán, Denis Poddubnyy, et al.
Bimekizumab Reduced MRI Inflammatory Lesions in Patients with Axial Spondyloarthritis: Week 52 Results from the BE MOBILE 1 and 2 Phase 3 Studies
Xenofon Baraliakos, Victoria Navarro-Compán, Denis Poddubnyy, et al.
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
John R. Ingram, Martina Porter, Raj Chovatiya, et al.
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
John R. Ingram, Martina Porter, Raj Chovatiya, et al.
Bimekizumab response through 3 years in patients with plaque psoriasis who stopped and re-started treatment
Antonio Costanzo, Kim Papp, C.E.M. Griffiths, et al.
Bimekizumab response through three years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Results from the open-label extension of BE RADIANT
Richard G. Langley, Pablo Fernandez-Peñas, James Krueger, et al.
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Kenneth B. Gordon, Diamant Thaci, Melinda Gooderham, et al.
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Infection rates using pooled data from up to three years of treatment in five phase 3/3b clinical trials
Richard B. Warren, Yukari Okubo, Lynda Spelman, et al.
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Safety topics of interest over time using pooled data from up to three years of treatment in five phase 3/3b clinical trials
Diamant Thaci, Shinichi Imafuku, Melinda Gooderham, et al.
Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)
Andrew Blauvelt, Kristina C. Duffin, Nina Magnolo, et al.
Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis who were Biologic DMARD‑Naïve or had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies
M. Elaine Husni, Philip J. Mease, Joseph F. Merola, et al.
Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis who were Biologic DMARD‑Naïve or had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies
M. Elaine Husni, Philip J. Mease, Joseph F. Merola, et al.
Bimekizumab Treatment Impact on Work Productivity in Biologic DMARD-Naïve and TNFi-IR Patients with Active Psoriatic Arthritis: Results up to 1 Year from Two Phase 3 Studies
Philip J. Mease, Dafna D. Gladman, Laure Gossec, et al.
Bimekizumab Treatment Improved Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain, Fatigue, and Morning Stiffness: 52-Week Results from Two Phase 3 Studies
Philip J. Mease, Maxime Dougados, Maureen Dubreuil, et al.
Bimekizumab Treatment in Patients with Active PsA and Prior Inadequate Response to TNF Inhibitors: Sustained Efficacy and Safety Results from a Phase 3 Study and its Open-Label Extension up to 1 Year
Laura C. Coates, Robert B.M. Landewé, Iain B. McInnes, et al.
Bimekizumab Treatment Resulted in Clinically Meaningful Improvements in the Psoriatic Arthritis Impact of Disease-12 (PsAID-12) Scores Using Pooled Results from Two Phase 3 Trials in Patients with Psoriatic Arthritis
Laure Gossec, Laura C. Coates, Ana‐Maria Orbai, et al.
Bimekizumab treatment resulted in rapid and sustained improvement in total and individual Bath Ankylosing Spondylitis Disease Activity Index components in patients with psoriatic arthritis: 1-year results from two phase 3 studies
Joseph F. Merola, Alice B. Gottlieb, Barbara Ink, et al.
Bimekizumab treatment resulted in sustained improvements in nail psoriasis and signs and symptoms of psoriatic arthritis in patients with baseline nail disease: 1-year pooled results from two phase 3 studies
Joseph F. Merola, Diamant Thaci, Barbara Ink, et al.
Bimekizumab treatment resulted in sustained improvements in pain and fatigue in patients with active psoriatic arthritis and baseline psoriasis: 1-year results from two phase 3 studies
Alice B. Gottlieb, Joseph F. Merola, Barbara Ink, et al.
Bimekizumab versus secukinumab continuous maintenance of PASI 90 and PASI 100 responses through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial
J. F. Merola, C. Conrad, P. Foley, et al.
Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial
Kilian Eyerich, Alice B. Gottlieb, Stefano Piaserico, et al.
Bimekizumab-Treated Patients with Active PsA Showed Sustained Improvement in Disease Symptoms Assessed by the PsA Impact of Disease (PsAID)-12 Questionnaire: 1-Year Results Reported from Two Phase 3 Studies
Dafna D. Gladman, Laura C. Coates, Maarten de Wit, et al.
Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints in Axial Spondyloarthritis and Implications for Recruitment in Clinical Studies
Xenofon Baraliakos, Pedro M. Machado, Lars Bauer, et al.
Durability of response among patients with psoriatic arthritis (PsA) using biological or targeted synthetic disease-modifying antirheumatic drugs in the CorEvitas PsA/spondyloarthritis registry
Alexis R. Ogdie, Chao Song, Nicole Middaugh, et al.
Durability of Response Among Patients with Psoriatic Arthritis (PsA) Using Biological or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/Spondyloarthritis Registry
Alexis R. Ogdie, Chao Song, Nicole Middaugh, et al.
Efficacy of Certolizumab Pegol in Preventing Anterior Uveitis Flares Compared with Standard Non-Biologic Treatment: A Matched Control Study in High-Risk Patients with Axial Spondyloarthritis
Nigil Haroon, Zeynep Baskurt, Tina Chim, et al.
Identification of Responder and Disease Activity Thresholds for the Psoriatic Arthritis Impact of Disease-12 (PsAID-12) Questionnaire Using Pooled Data from Two Phase 3 Trials of Bimekizumab in Patients with Psoriatic Arthritis
Laure Gossec, Laura C. Coates, Ana-Maria Orbai, et al.
IHS4 Outcomes with Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Results from the BE HEARD I & II Phase 3 Trials
Christos C. Zouboulis, Joslyn S. Kirby, Thrasyvoulos Tzellos, et al.
Impact of the CIMplicity® Patient Support Program on Persistence to Certolizumab Pegol Treatment: A Retrospective Cohort Analysis of Claims Data in the United States
Aimee Near, Srihari Jaganathan, Chao Song, et al.
Itching, skin pain and scaling in patients with plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and Psoriasis Symptoms and Impacts Measure responses
Andreas Pinter, Matthias Augustin, David Pariser, et al.
Long-term safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 5-year results from a phase 2b study and its open-label extension
Atul Deodhar, Victoria Navarro-Compán, Denis Poddubnyy, et al.
Long-Term Safety and Efficacy of Bimekizumab in Patients with Active Ankylosing Spondylitis: 5-Year Results from a Phase 2b Study and its Open-Label Extension
Atul Deodhar, Victoria Navarro-Compán, Denis Poddubnyy, et al.
Long-Term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Results from Pooled Phase 2b/3 Studies
Philip J. Mease, Denis Poddubnyy, Ana-Maria Orbai, et al.
Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials
Martin Rudwaleit, Matthew A. Brown, Floris Alexander van Gaalen, et al.
Management and treatment patterns in psoriasis and psoriatic arthritis
Rola Gharib, Marc Bénard, Zuzana Mohrova, et al.
Normalization of molecular signatures associated with pruritis in plaque psoriasis correlate with itch resolution following bimekizumab treatment
Ioana Cutcutache, Joe Rastrick, Alex Ferecsko, et al.
Patient and Physician Preferences for Attributes Associated with Biologic Treatments for Hidradenitis Suppurativa
John R. Ingram, Christopher Sayed, Rickie Jacobs-Lee, et al.
Patients with psoriatic arthritis at biologic therapy switch: The CorEvitas psoriasis registry
Philip J. Mease, Eric Jones, Adam Sima, et al.
Patients with Psoriatic Arthritis at Biologic Therapy Switch: The CorEvitas Psoriasis Registry
Philip J. Mease, Eric Jones, Adam Sima, et al.
Performance Analysis of a Deep Learning Algorithm to Detect Positive SIJ MRI According to the ASAS Definition in axSpA Patients
Joeri Nicolaes, Evi Tselenti, Theodore Aouad, et al.
Performance Analysis of a Deep Learning Algorithm to Detect Positive SIJ MRI According to the ASAS Definition in axSpA Patients
Joeri Nicolaes, Evi Tselenti, Theodore Aouad, et al.
Real world data on the 1-year treatment of psoriasis with the use of certolizumab pegol in women of child-bearing potential
Khusru Asadullah, M.C. Fargnoli, De Simone, et al.
Real-world data on the use of certolizumab pegol for the treatment of moderate to severe plaque psoriasis: 1-year results from a prospective non-interventional cohort study
Richard B. Warren, Bernhard Korge, David V. Sarro, et al.
Real-world patient characteristics and prior treatment history of bimekizumab patients in Germany
Alexander Zink, Anna Ramond, Aijing Shang, et al.
Resolution of Enthesitis and Peripheral Arthritis with Bimekizumab in Patients with Axial Spondyloarthritis: Week 52 Results from the BE MOBILE 1 and BE MOBILE 2 Phase 3 Studies
Marina Magrey, Marleen G.H. Van de Sande, Maxime Breban, et al.
Rheumatology Care Journey Among Patients with Psoriatic Arthritis or Axial Spondyloarthritis in the United States
Reeti Joshi, Chao Song, Silky Beaty, et al.
Self-reported pain outcomes in patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from two phase 3 trials (CIMPASI-1 and CIMPASI-2)
Alice B. Gottlieb, Julia-Tatjana Maul, Lynda Spelman, et al.
Stable plasma concentration of certolizumab pegol is associated with persistent clinical improvement among patients with moderate to severe plaque psoriasis: Data from CIMPASI-1 and CIMPASI-2
Luis Puig, Paolo Gisondi, Andreas Pinter, et al.
Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumor necrosis factor inhibitors: Results from the Phase 3 BE COMPLETE study and its open-label extension up to 1 year
Laura C. Coates, Robert B.M. Landewé, Iain B. McInnes, et al.
Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumor necrosis factor inhibitors: Results from the Phase 3 BE COMPLETE study and its open-label extension up to 1 year
Laura C. Coates, Robert B.M. Landewé, Iain B. McInnes, et al.
Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Results from the Phase 3 BE COMPLETE study and its open-label extension up to 1 year
Laura C. Coates, Robert B.M. Landewé, Iain B. McInnes, et al.
Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Results from the phase 3 BE COMPLETE Study and its open-label extension up to 1 year
Laura C. Coates, Robert B.M. Landewé, Iain B. McInnes, et al.
Sustained Efficacy and Safety of Bimekizumab in Patients with Active Psoriatic Arthritis and Prior Inadequate Response to Tumour Necrosis Factor Inhibitors: Results from the Phase 3 BE COMPLETE Study and its Open-Label Extension up to 1 Year
Laura C. Coates, Robert B.M. Landewé, Iain B. McInnes, et al.
Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Results from the Phase 3 BE COMPLETE study and its open-label extension up to 1 year
Laura C. Coates, Robert B.M. Landewé, Iain B. McInnes, et al.
Temporal impact of infection-related treatment emergent adverse events on patient-reported outcomes in patients with moderate to severe psoriasis – analysis of the German national registry PsoBest
Matthias Augustin, Toni M. Janke, Tanja Heidbrede, et al.
Treatment history and symptom severity in patients with moderate to severe plaque psoriasis being initiated on bimekizumab: Use during the 1st year of routine clinical practice
Khusru Asadullah, Bernhard Korge, Andreas Pinter, et al.
Treatment Journey of Patients with Non-Radiographic Axial Spondyloarthritis in a US Rheumatology Office Setting: A Retrospective Chart Review
Robert Low, Sari Hopson, Silky Beaty, et al.
Understanding the Pathobiology of Axial Spondyloarthritis and Psoriatic Arthritis
Kristine Kuhn
Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment Over 52 Weeks: Results from Two Phase 3 Studies
Martin Rudwaleit, Victoria Navarro-Compán, Atul Deodhar, et al.